Influence of R-CHOP therapy on immune system restoration in patients with b-cell lymphoma

Oncology (Switzerland)

Volumn 91, Issue 6, 2016, Pages 302-310

  Ito, Kaori ^a,b   Okamoto, Masataka ^b   Inaguma, Yoko ^b   Okamoto, Akinao ^b   Ando, Maiko ^a,b   Ando, Yosuke ^a   Tsuge, Masahiro ^a   Tomono, Ayana ^a   Kakumae, Yukiko ^a   Hayashi, Takahiro ^a   Yamada, Shigeki ^a   Emi, Nobuhiko ^b  

^a FUJITA HEALTH UNIVERSITY HOSPITAL   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

B cell lymphoma; CD4+ lymphocyte; Immune system; R CHOP therapy; Serum IgG

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN G; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CELLULAR IMMUNITY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT DURATION; ADVERSE EFFECTS; BLOOD; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LYMPHOMA, B-CELL; MIDDLE AGED; T LYMPHOCYTE; TIME FACTOR;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTIGENS, CD3; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; INFECTION; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PREDNISONE; RITUXIMAB; T-LYMPHOCYTES; TIME FACTORS; VINCRISTINE;

EID: 84989225427     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000449251     Document Type: Article

References (26)

1. Persky DO, Unger JM, Spier CM, Stea B, Le-Blanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP; Southwest Oncology Group. Phase II study of rituximab plus three cycles of CHOP, and involved-field radiotherapy for patients with limited-stage aggressive Bcell lymphoma. Southwest Oncology Group study 0014. J Clin Oncol 2008; 26: 2258-2263
2. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391
3. Fisher RI, Le Blanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447-8452
4. van Meerten T, Hagenbeek A. CD20-targeted therapy the next generation of antibodies. Semin Hematol 2010; 47: 199-210
5. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103: 2738-2743
6. Hiddemann W, Kneba M, Drevling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wormann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trumper L, Aldaoud A, Parwaresch R, Unterhalt M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone. results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732
7. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242
8. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42-51
9. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical, and molecular remission in patients with lowgrade or follicular non-Hodgkins lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711-4716
10. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-3274
11. Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Leger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF. Single agent rituximab in patients with follicular or mantle cell lymphoma. clinical, and biological factors that are predictive of response, and event-free survival as well as the effect of rituximab on the immune system a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005; 16: 1675-1682
12. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma. half of patients respond to a fourdose treatment program. J Clin Oncol 1998; 16: 2825-2833
13. Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF, Betticher DC, Schefer H, Pichert G, Stahel R, Ketterer N, Bargetzi M, Cerny T; Swiss Group for Clinical Cancer Research. Effect of single agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23: 705-711
14. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival, and response duration compared with the standard weekly .4 schedule. Blood 2004; 103: 4416-4423
15. Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, Shenoy S. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer 2008; 50: 822-825
16. Kurokawa T, Hase M, Tokuman N, Yoshida T. Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. Hematol Oncol 2011; 29: 5-9
17. Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, Kelly J, Milner EC, Fisher RI, Sanz I. B-cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007; 122: 139-145
18. Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine, and associated with hypogammaglobulinemia a frequently unrecognized, and easily treatable complication. Ann Oncol 2006; 17: 1424-1427
19. Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab, and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013; 13: 106-111
20. Saikia TK, Menon H, Advani SH. Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma, and corrected with IVIG. Ann Oncol 2001; 12: 1493-1494
21. Yokohama A, Tsukamoto N, Uchiumi H, Handa H, Matsushima T, Karasawa M, Murakami H, Nojima Y. Durable remission induced by rituximab-containing chemotherapy in a patient with primary refractory Burkitt's lymphoma. Ann Hematol 2004; 83: 120-123
22. De La Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, Cambridge G. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab. relationship with B-cell kinetics. Rheumatology 2012; 51: 833-840
23. Marco H, Smith RM, Jones RB, Guerry MJ, Catapano F, Burns S, Chaudhry AN, Smith KG, Jayne DR the effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord 2014; 15: 178-186
24. Garcia Munoz R, Izquierdo-Gil A, Munoz A, Roldan-Galiacho V, Rabasa P, Panizo C. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia, and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol 2014; 93: 1879-1887
25. Ito K, Okamoto M, Ando M, Kakumae Y, Okamoto A, Inaguma Y, Tokuda M, Yanada M, Yamada S, Emi N. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma, and mantle cell lymphoma. Leuk Lymphoma 2015; 56: 1123-1125
26. Gafter-Gvili A, Polliack A. Bendamustine associated immune suppression, and infections during therapy of hematological malignancies. Leuk Lymphoma 2016; 57: 512-519